Berman Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Berman Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$61K	Buy	82 +14	+21%	+$10.5K	0.01%	595
2021 Q2	$43K	Hold	68	–	–	0.01%	635
2021 Q1	$38K	Buy	68 +1	+1%	+$592	0.01%	577
2020 Q4	$39K	Sell	67 -2	-3%	-$1.14K	0.01%	471
2020 Q3	$35K	Sell	69 -2	-3%	-$1.01K	0.01%	435
2020 Q2	$32K	Sell	71 -13	-15%	-$5.74K	0.01%	418
2020 Q1	$29K	Sell	84 -7	-8%	-$2.57K	0.01%	397
2019 Q4	$33K	Hold	91	–	–	0.01%	407
2019 Q3	$30K	Buy	91 +6	+7%	+$1.96K	0.01%	402
2019 Q2	$26K	Buy	+85	New	+$25.5K	0.01%	438

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Berman Capital Advisors's BIO Position: Q3 2021 in Review

Berman Capital Advisors increased its Bio-Rad Laboratories Class A (BIO) stake by 21% in Q3 2021, buying an estimated $10.5K and bringing the position to 82 shares worth $61K. The position accounts for 0.01% of the portfolio, ranked #595.

Berman Capital Advisors first reported a position in BIO in Q2 2019 and has held it in 10 quarters since. 508 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

Berman Capital Advisors held 82 shares of Bio-Rad Laboratories Class A worth $61K as of Q3 2021.
Berman Capital Advisors bought 14 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $10.5K.
Bio-Rad Laboratories Class A made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #595 holding.
Berman Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q2 2019 and has held it in 10 quarters since.
508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.